Do GLP-1 drugs actually trigger panic attacks?

What did @natalyamakes actually say?

She described experiencing severe panic attacks and intrusive thoughts about self-harm while on a GLP-1 medication, calling it worse than three natural childbirths. She's not anti-GLP-1, but she's warning others. She also claims pharmacy staff are now routinely warning patients about this symptom. That's a specific, falsifiable set of claims worth examining.

To be precise about the intrusive thoughts: she said "it was never a serious thing" but described persistent ideation that felt like her only escape. That distinction matters clinically, but it doesn't make the experience less alarming or less real.

Does the science back this up?

Partly, yes. GLP-1 receptor agonists do have documented psychiatric adverse events, and the evidence has been accumulating faster than the FDA has moved on labeling.

The most significant signal came from the European Medicines Agency (EMA), which in 2023 opened a formal review into suicidal ideation and self-harm reports linked to semaglutide and liraglutide. The review ultimately concluded the data did not establish a causal link, but the EMA acknowledged the signal was real enough to investigate. The FDA has added language to prescribing information noting psychiatric events as a consideration.

On panic attacks specifically, the picture is murkier. GLP-1 receptors are expressed in areas of the brain involved in anxiety regulation, including the amygdala and hypothalamus (Anderberg et al., 2016, Neuropharmacology). Animal studies have shown mixed results: some suggesting anxiolytic effects, others showing increased anxiety-like behavior depending on dose and context. There is no large randomized trial that has specifically measured panic attack incidence as a primary outcome.

What does exist is a growing pharmacovigilance record. A 2023 analysis of the FDA Adverse Event Reporting System (FAERS) found disproportionate reporting of anxiety and panic-related events for semaglutide compared to background rates. That's hypothesis-generating, not causal, but it's not nothing.

What did they get wrong (or right)?

She got the core experience right, and probably more right than wrong on the general claim. Psychiatric side effects, including anxiety, panic, and intrusive thoughts, are documented in the adverse event literature for GLP-1 drugs. Dismissing her account as purely psychological or coincidental would be a mistake.

Where she drifts into less solid territory is the pharmacy warning claim. She says staff "now warn people who are getting GLP-1s" about panic attacks as a standard symptom. There is no FDA-mandated labeling requirement for pharmacists to counsel specifically about panic attacks. If individual pharmacies are doing this, it reflects their own risk communication policies, not a regulatory standard. Presenting this as systemic or official overstates it.

She also frames the intrusive thoughts as almost a physical compulsion, "my body was like the only way to get out of this." That description is consistent with what clinicians recognize as ego-dystonic intrusive thoughts, which are a known feature of severe anxiety, not necessarily suicidal intent. She's right to distinguish between the two, but the framing could still alarm viewers who don't know that difference.

What should you actually know?

If you're on a GLP-1 and you're experiencing new anxiety, panic attacks, or any intrusive thoughts, this warrants a direct conversation with your prescriber, not a TikTok comment section. These symptoms are in the adverse event literature. They are not universally experienced, but they are not imagined either.

The mechanism is not well understood. GLP-1 receptors in the central nervous system influence dopamine signaling, stress response, and appetite regulation simultaneously. Disrupting that system, especially at higher doses used for weight management rather than glycemic control, may have psychiatric effects that differ by individual neurobiology.

Importantly, stopping a GLP-1 abruptly is not automatically safe either. Any medication change should involve your provider. FormBlends strongly recommends reporting psychiatric symptoms to your care team immediately rather than discontinuing on your own.

• The EMA investigated suicidal ideation signals for semaglutide and liraglutide in 2023.
• GLP-1 receptors are present in anxiety-regulating brain regions.
• FAERS data shows disproportionate anxiety and panic reports for semaglutide.
• No current FDA label requires pharmacist counseling specifically about panic attacks.
• Intrusive thoughts and panic do not automatically indicate suicidal intent, but both require clinical follow-up.